Literature DB >> 20354189

The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2.

Michael Zimmer1, Justin Lamb, Benjamin L Ebert, Mary Lynch, Christopher Neil, Emmett Schmidt, Todd R Golub, Othon Iliopoulos.   

Abstract

Hypoxia-inducible factors 1 and 2 (HIF1 and HIF2) are heterodimeric transcription factors consisting of alpha regulatory subunits and a constitutively expressed beta subunit. The expression of alpha regulatory subunits is promoted by hypoxia, cancer-associated mutations, and inflammatory cytokines. Thus, HIF1 and HIF2 provide a molecular link between cancer and inflammation. We have recently identified novel small molecules that selectively inhibit translation of the HIF2a message and thereby powerfully inhibit the expression of HIF2a target genes. We report here that Connectivity Map analysis links three of these compounds to the anti-inflammatory cytokine 15-deoxy-Delta(12,14)-prostaglandin J(2) (PGJ(2)). As with our identified compounds, PGJ(2) inhibits translation of the HIF2a message in a mammalian target of rapamycin-independent manner by promoting the binding of iron regulatory protein-1 (IRP1) to a noncanonical iron responsive element (IRE) embedded within the 5'-untranslated region of the HIF2a message. The IRE is necessary and sufficient for mediating the effect. Mutation of the IRE sequence, or downregulation of IRP1 expression, blocks the effect of PGJ(2) on HIF2a translation. This is the first report of an endogenous natural molecule regulating HIF2a translation, and it suggests that part of the anti-inflammatory and putative antineoplastic effects of PGJ(2) may be mediated through inhibition of HIF2a within tumor epithelial cells themselves and/or mesenchymal cells of the tumor microenvironment. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20354189      PMCID: PMC2861799          DOI: 10.1158/0008-5472.CAN-09-2877

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  HIF-1alpha is essential for myeloid cell-mediated inflammation.

Authors:  Thorsten Cramer; Yuji Yamanishi; Björn E Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S Firestein; Hans Peter Gerber; Napoleone Ferrara; Randall S Johnson
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

Review 2.  HIF-1 as a target for drug development.

Authors:  Amato Giaccia; Bronwyn G Siim; Randall S Johnson
Journal:  Nat Rev Drug Discov       Date:  2003-10       Impact factor: 84.694

3.  Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.

Authors:  Xin Hua Liu; Alexander Kirschenbaum; Min Lu; Shen Yao; Amy Dosoretz; James F Holland; Alice C Levine
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

4.  The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells.

Authors:  Jian Wang; Joan L Buss; Guohua Chen; Prem Ponka; Kostas Pantopoulos
Journal:  FEBS Lett       Date:  2002-10-09       Impact factor: 4.124

5.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.

Authors:  M Sonoshita; K Takaku; N Sasaki; Y Sugimoto; F Ushikubi; S Narumiya; M Oshima; M M Taketo
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

6.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma.

Authors:  L Chastine Bell-Parikh; Tomomi Ide; John A Lawson; Peter McNamara; Muredach Reilly; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

7.  Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Authors:  Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

8.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1.

Authors:  Ryo Fukuda; Brian Kelly; Gregg L Semenza
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

9.  15-Deoxy-Delta(12,14)-prostaglandin-J(2) reveals a new pVHL-independent, lysosomal-dependent mechanism of HIF-1alpha degradation.

Authors:  Gemma Olmos; María I Arenas; Raquel Bienes; María Jose Calzada; Julián Aragonés; Maria Laura Garcia-Bermejo; Manuel O Landazuri; Javier Lucio-Cazaña
Journal:  Cell Mol Life Sci       Date:  2009-05-21       Impact factor: 9.261

10.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  19 in total

1.  Drug discovery in a multidimensional world: systems, patterns, and networks.

Authors:  Joel T Dudley; Eric Schadt; Marina Sirota; Atul J Butte; Euan Ashley
Journal:  J Cardiovasc Transl Res       Date:  2010-07-31       Impact factor: 4.132

2.  Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing.

Authors:  Joe G N Garcia; Roberto F Machado; Victor R Gordeuk; Xu Zhang; Wei Zhang; Shwu-Fan Ma; Galina Miasniakova; Adelina Sergueeva; Tatiana Ammosova; Min Xu; Sergei Nekhai; Mehdi Nourai; Michael S Wade; Josef T Prchal
Journal:  Blood Cells Mol Dis       Date:  2013-08-28       Impact factor: 3.039

Review 3.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling.

Authors:  Paul D Ray; Bo-Wen Huang; Yoshiaki Tsuji
Journal:  Cell Signal       Date:  2012-01-20       Impact factor: 4.315

4.  Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.

Authors:  Rima Hajjo; Vincent Setola; Bryan L Roth; Alexander Tropsha
Journal:  J Med Chem       Date:  2012-06-11       Impact factor: 7.446

Review 5.  Mammalian iron metabolism and its control by iron regulatory proteins.

Authors:  Cole P Anderson; Macy Shen; Richard S Eisenstein; Elizabeth A Leibold
Journal:  Biochim Biophys Acta       Date:  2012-05-17

6.  Using functional signature ontology (FUSION) to identify mechanisms of action for natural products.

Authors:  Malia B Potts; Hyun Seok Kim; Kurt W Fisher; Youcai Hu; Yazmin P Carrasco; Gamze Betul Bulut; Yi-Hung Ou; Mireya L Herrera-Herrera; Federico Cubillos; Saurabh Mendiratta; Guanghua Xiao; Matan Hofree; Trey Ideker; Yang Xie; Lily Jun-shen Huang; Robert E Lewis; John B MacMillan; Michael A White
Journal:  Sci Signal       Date:  2013-10-15       Impact factor: 8.192

7.  New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.

Authors:  Ramaprasad Srinivasan; Christopher J Ricketts; Carole Sourbier; W Marston Linehan
Journal:  Clin Cancer Res       Date:  2015-01-01       Impact factor: 12.531

Review 8.  Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential.

Authors:  Rahul Palchaudhuri; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2010-12-23       Impact factor: 5.100

9.  The IRP1-HIF-2α axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption.

Authors:  Sheila A Anderson; Christopher P Nizzi; Yuan-I Chang; Kathryn M Deck; Paul J Schmidt; Bruno Galy; Alisa Damnernsawad; Aimee T Broman; Christina Kendziorski; Matthias W Hentze; Mark D Fleming; Jing Zhang; Richard S Eisenstein
Journal:  Cell Metab       Date:  2013-02-05       Impact factor: 27.287

Review 10.  The VHL/HIF axis in clear cell renal carcinoma.

Authors:  Chuan Shen; William G Kaelin
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.